Healthcare / BiotechnologyNasdaqGM
$0.81
-0.06 (-6.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-67.3M · quality 38.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$128M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1490.3%
↓Gross Margin
N/A
•Debt/Equity
6.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-141.0M · FCF $-90.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $93000.00 | $120000.00 | — |
| Net Income | $-141.0M | $-141.0M | $-68.7M | $-77.1M | $-46.5M |
| EBITDA | $-95.7M | $-95.7M | $-92.9M | $-50.5M | $-48.9M |
| EPS | -0.92 | -0.92 | -1.62 | -1.98 | -1.34 |
| Gross Margin | — | — | 46.2% | 35.8% | — |
| Operating Margin | — | — | -100571.0% | -42363.3% | — |
| Net Margin | — | — | -73864.5% | -64242.5% | — |
| Balance Sheet | |||||
| Debt/Equity | 6.52 | 6.52 | 2.20 | -0.27 | -0.08 |
| Current Ratio | 4.28 | 4.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-90.9M | $-90.9M | $-67.3M | $-43.2M | $-46.3M |
| Returns | |||||
| ROE | -1490.3% | -1490.3% | -241.7% | 23.7% | 18.4% |
| Valuation | |||||
| P/B | 13.11 | 13.11 | 3.37 | — | — |
| Growth & Yield | |||||
| Revenue Growth | — | — | -22.5% | — | — |
| EPS Growth | 43.3% | 43.3% | 18.3% | -48.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.62 → -0.92
Residual
-57.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.